Applications

Myelination

Evaluate remyelinating drug efficacy by quantifying myelin loss, recovery, and repair. CNS-3D Myelinated Organoids incorporate neurons, astrocytes, and oligodendrocytes to support studies of demyelination and remyelination in human context.

Model Human Demyelinating Disease Biology

The study of myelination has historically relied on animal models, where myelin loss and repair can occur faster and more completely than in humans, creating a translational gap for demyelinating diseases such as multiple sclerosis. As the only commercially available 3D brain organoid model incorporating oligodendrocytes.

CNS-3D Myelinated Organoids enable researchers to capture myelin injury, recovery, and repair in a functional human CNS context. Integrated myelin, gene expression, and calcium imaging endpoints reveal whether drug candidates restore myelin integrity and improve neural network activity.

Advantages

Quantify myelin loss, recovery, and repair.

Study myelin loss, recovery, and repair in a functional human 3D CNS model containing neurons, astrocytes, and oligodendrocytes.

Human
Myelin Biology

The only commercially available 3D brain model incorporating oligodendrocytes.

Drug-Induced Demyelination

Model drug-induced myelin injury to evaluate demyelination risk and disease-relevant mechanisms.

Functional
Neural Impact

Assess whether myelin repair is associated with improved neuronal network activity.

Multiplexed
CNS Endpoints

Integrate myelin marker quantification, functional calcium imaging, and molecular profiling.

Use Case

Myelination

Evaluate remyelinating drug efficacy by quantifying myelin loss, recovery, and repair.

CNS-3D Myelinated Organoids enable the quantification of myelin loss, natural recovery, and drug-induced remyelination in a human context that better reflects the slower, often incomplete myelin loss and repair dynamics seen in human disease. Integrated structural, functional, and molecular endpoints reveal whether drug candidates restore myelin integrity and improve neural function.

Representative image of CNS-3D Myelinated Organoid at 12 weeks, showing neurons (NFH, magenta) and myelinating oligodendrocytes (MBP, green).

Offerings

Products & Services

Investigate demyelinating disease biology and remyelinating drug efficacy with assay-ready products for in-house studies or through CNS Services for end-to-end study design, execution, and analysis.